Neuropathological changes in AD precede clinical manifestations [3], thus several biomarkers of the AD continuum have been recognized, such as cerebrospinal fluid amyloid beta (CSF Aβ42) [4,5], Tau (CSF Tau) [6] and Phosphorylated Tau (CSF PhTau), which may be present in preclinical stages, as well. This evidence concerns the gene MAPT and Alzheimer disease.